Robert Bindert Huizinga - 25 Oct 2021 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Role: EVP of Research
Signature: /s/ Robert Bindert Huizinga
Issuer symbol: AUPH
Transactions as of: 25 Oct 2021
Net transactions value: -$3,563,500
Form type: 4
Filing time: 26 Oct 2021, 16:33:24 UTC
Previous filing: 22 Sep 2021
Next filing: 04 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AUPH	Common Stock	Options Exercise	$304,000	+95,000	+94%	$3.20	195,728	25 Oct 2021	Direct	F1
transaction	AUPH	Common Stock	Sale	$3,867,500	-130,000	-66%	$29.75	65,728	25 Oct 2021	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AUPH	Stock Option (right to buy)	Options Exercise	$0	-95,000	-96%	$0.000000	3,864	25 Oct 2021	Common Stock	95,000	$3.20	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
F2	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3	The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $29.50 to $30.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4	The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date.